Newborn screening (NBS) is a critical public health program that identifies serious but treatable rare diseases in newborns before symptoms appear. By detecting metabolic, genetic, and endocrine disorders early, NBS enables timely medical interventions, improving survival rates and quality of life. Expanding NBS programs globally can help reduce the diagnostic odyssey for rare disease patients and ensure better health outcomes from infancy.